Patents Assigned to Efamol Holding PLC
-
Patent number: 5614208Abstract: Atopic eczema, breast pain or premenstrual syndrome are treated by administering to a person in need of same a composition containing at least 20% di-linoleoyl-mono-gamma-linolenyl glycerol by weight.Type: GrantFiled: February 14, 1996Date of Patent: March 25, 1997Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5580556Abstract: The use of one or more of gamma-linolenic acid, dihomo-gamma-linolenic acid and arachidonic acid for the manufacture of a medicament for use in enhancement of the anti-viral, anti-cancer or anti-inflammatory effects of interferons; the medicament containing or being for use with a medicament containing one or more interferons when not solely for enhancement of the effect of endogenous interferons.Type: GrantFiled: January 3, 1995Date of Patent: December 3, 1996Assignee: Efamol Holdings PLCInventor: David F. Horrobin
-
Patent number: 5552150Abstract: A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-gamma-linolenyl-glycerol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.Type: GrantFiled: November 30, 1993Date of Patent: September 3, 1996Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5422115Abstract: Methods of treatment of the human or animal body are provided to combat conditions responsive to lithium and/or C.sub.18-22 polyunsaturated fatty acid therapy, including conditions associated with essential lithium deficiency, and also transfer of lipid-enveloped viruses between humans or animals or between cells within a human or animal body. The methods include administration of an effective amount of a lithium salt of a C.sub.18-22 polyunsaturated fatty acid. Devices for combatting transmission of viral diseases including lithium salts of a C.sub.18-22 polyunsaturated fatty acid are also provided.Type: GrantFiled: October 20, 1992Date of Patent: June 6, 1995Assignee: Efamol Holding PLCInventor: David F. Horrobin
-
Patent number: 5328691Abstract: A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-gamma-linolenyl-glycerol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.Type: GrantFiled: June 1, 1992Date of Patent: July 12, 1994Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Yung-Sheng Huang
-
Patent number: 5318991Abstract: Reduction of urinary calcium excretion in humans or animals by the administration of GLA or DGLA as much or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, is also useful in the treatment of nephrocalcinosis, renal stones and osteoporosis.Type: GrantFiled: April 22, 1993Date of Patent: June 7, 1994Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Alfred C. Buck
-
Patent number: 5276020Abstract: Anti-virals wherein a linoleyl, gamma-linolenyl or other unsaturated long chain fatty acyl group is borne directly on a hydroxy or amino group of the sugar/sugar analogue or heterocyclic moiety of a nucleoside or nucleoside analogue.Type: GrantFiled: December 14, 1992Date of Patent: January 4, 1994Assignee: Efamol Holdings plcInventors: David F. Horrobin, John C. M. Stewart, Michael D. Winther
-
Patent number: 5223271Abstract: The present invention provides a method of treatment and/or prophylaxis of the human or animal body to combat Molluscum Contagiosum, said treatment comprising topically administering a therapeutically or prophylactically effective amount of a physiologically acceptable lithium compound to affected areas on said body.It also extends to pharmaceutical compositions comprising a physiologically acceptable lithium compound together with at least one keratolytic and/or skin penetration assisting agent and at least one pharmaceutically acceptable carrier or excipient.Type: GrantFiled: September 24, 1991Date of Patent: June 29, 1993Assignee: Efamol Holdings PLCInventor: David F. Horrobin
-
Patent number: 5216142Abstract: Anti-virals wherein a linoleyl, gamma-linolenyl or other unsaturated long chain fatty acyl group is borne directly on a hydroxy or amino group of the sugar/sugar analogue or heterocyclic moiety of a nucleoside or nucleoside analogue.Type: GrantFiled: April 10, 1990Date of Patent: June 1, 1993Assignee: Efamol Holdings plcInventors: David F. Horrobin, John C. M. Stewart, Michael D. Winther
-
Patent number: 5198468Abstract: Treatment or prevention of memory loss with a medicament consisting of an n-6 essential fatty acid selected from GLA, DGLA, AA, adrenic acid and the 22:5 n-6 acid and an n-3 essential fatty acid selected from the 18:4 n-3 and 20:4 n-3 acids, EPA, the 22:5 n-3 acid and DHA.Type: GrantFiled: June 19, 1991Date of Patent: March 30, 1993Assignee: Efamol Holdings PlcInventor: David F. Horrobin
-
Patent number: 5178873Abstract: A method of inhibiting phospholipase A2 in the control of inflammation, wherein delta-6,9,12,15-octadecatetraenoic acid (stearidonic acid) and/or delta-8,11,14,17-eicosatetraenoic acid is administered alone or in a pharmaceutically acceptable diluent or carrier.Type: GrantFiled: May 23, 1991Date of Patent: January 12, 1993Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Michael J. Finnen
-
Patent number: 5162519Abstract: This invention provides novel compounds for therapy of tumors susceptible to necrosis when an appropriate compound is administered followed by illumination with light of a wavelength absorbed by the compound, the compounds being dihydro porphyrins of the formula, or the corresponding tetra-hydro porphyrins: ##STR1## where n=1 to 3 and each substituent R, the same or different and at the same or different position in its respective substituent phenyl ring, is an hydroxy group.Type: GrantFiled: November 26, 1990Date of Patent: November 10, 1992Assignee: Efamol Holdings plcInventors: Raymond Bonnett, Morris C. Berenbaum
-
Patent number: 5120760Abstract: Method of, and preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher n-6 series acides with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10 mg and 50 g of each acid.Type: GrantFiled: September 25, 1990Date of Patent: June 9, 1992Assignee: Efamol Holdings PLCInventor: David F. Horrobin
-
Patent number: 5116624Abstract: A pharmaceutical composition of GLA or DGLA and bioavailable selenium, optionally also with an 18:4 or higher n-3 EFA and/or bioavailable zinc.Type: GrantFiled: January 9, 1991Date of Patent: May 26, 1992Assignee: Efamol Holdings PLCInventors: David F. Horrobin, Frank Corrigan
-
Patent number: 5116871Abstract: The use of one or more of the 6-desaturated or higher EFAs of each of the n-6 and n-3 series for the manufacture of a medicament for use in the treatment of post-viral fatigue syndrome (otherwise known as myalgic encephalomyelitis (ME)).Type: GrantFiled: August 24, 1989Date of Patent: May 26, 1992Assignee: Efamol Holdings PLCInventors: David F. Horrobin, John C. M. Stewart
-
Patent number: 4997657Abstract: A composition, particularly an oral composition, for improving the smoothness of the skin, wherein GLA or DGLA or both as such or in the form of physiologically acceptable and equivalent derivatives are brought into administrable form with a carrier or diluent.Type: GrantFiled: March 9, 1989Date of Patent: March 5, 1991Assignee: Efamol Holdings, plcInventors: David F. Horrobin, John C. M. Stewart
-
Patent number: 4992257Abstract: This invention provides novel compounds for therapy of tumors susceptible to necrosis when an appropriate compound is administered followed by illumination with light of a wavelength absorbed by the compound, the compounds being dihydro porphyrins of the formula, or the corresponding tetra-hydro prophyrins: ##STR1## where n=1 to 3 and each substitutent R, the same or different and at the same or different position in its respective substituent phenyl ring, is an hydroxy group.Type: GrantFiled: March 2, 1989Date of Patent: February 12, 1991Assignee: Efamol Holdings PLCInventors: Raymond Bonnett, Morris C. Berenbaum
-
Patent number: 4977187Abstract: Method of, and preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher N-6 series acids with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10 mg and 50 g of each acid.Type: GrantFiled: June 1, 1989Date of Patent: December 11, 1990Assignee: Efamol Holdings PLCInventor: David F. Horrobin
-
Patent number: 4970076Abstract: Composition of a cyclosporin and GLA and DGLA or derivative thereof convertible in the body thereto alone or in a pharmaceutical diluent or carrier.Type: GrantFiled: December 6, 1988Date of Patent: November 13, 1990Assignee: Efamol Holdings PLCInventor: David F. Horrobin